Ellicott City, M.D., April 30, 2015 – The Society for Clinical Research Sites (SCRS), the global trade organization fully dedicated to representing the interests of clinical research sites, and Total Clinical Trial Management (TCTM), an emerging contract research organization (CRO) based in Dallas, Texas, today announced through the TCTM Scholarship Program over 500 clinical research sites have been awarded one-year SCRS memberships. The SCRS Site Scholarship Program awards membership to qualifying sites striving for excellence in clinical research who are not current or previous SCRS members.
“SCRS applauds TCTM’s commitment to promoting greater site sustainability for clinical research sites globally by sponsoring SCRS membership for over 500 sites,” comments Christine Pierre, SCRS President. “SCRS provides the advanced knowledge, resources, and mentorship sites need to develop best clinical practices and business acumen for sustainability. We are pleased that the SCRS Site Scholarship Program is gaining considerable momentum and enabling more sites access to the tools, resources, and training provided by SCRS critical to the conduct of quality research.”
“TCTM is pleased to support SCRS’ important work in this significant capacity,” comments Ryan Sunday, Senior Director of Operations and Business Development, TCTM. “As the pharma industry evolves, site health and trial quality are critical areas of focus for TCTM. We are proud to have an opportunity to contribute in a meaningful way to the success of our future site partners around the world.”
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Pfizer Reports Strong Phase III Results for Hympavzi in Hemophilia Patients with Inhibitors
June 26th 2025The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with hemophilia A or B with inhibitors, offering a promising new prophylactic option for a population with limited therapeutic choices.